Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nabriva Therapeutics PLC - ADR    NBRV

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
9.6(c) 9.61(c) 9.37(c) 8.83(c) 8.81 Last
25 441 26 500 32 775 39 468 3 718 Volume
-4.00% +0.10% -2.50% -5.76% -0.23% Change
More quotes
Financials ($)
Sales 2017 5,30 M
EBIT 2017 -62,4 M
Net income 2017 -65,1 M
Finance 2017 156 M
Yield 2017 -
Sales 2018 4,99 M
EBIT 2018 -76,3 M
Net income 2018 -79,1 M
Debt 2018 21,5 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 15,3x
EV / Sales2018 51,8x
Capitalization 237 M
More Financials
Company
Nabriva Therapeutics Plc is a holding company, which operates as a clinical-stage biopharmaceutical firm.It engages in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics.The company was founded on March 1, 2017 and... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Surperformance© ratings of Nabriva Therapeutics PLC -
Trading Rating : Investor Rating :
More Ratings
Latest news on NABRIVA THERAPEUTICS PLC -
08/07 Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent..
08/02 Nabriva Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Confer..
07/11 Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Offi..
06/26 Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board
06/26 Nabriva Therapeutics plc Successfully Concludes Tender Offer for Outstanding..
06/24 PFIZER : FDA To Discuss Mylotarg Again And Nabriva`s Pivotal Antibiotic Data
06/19 NABRIVA THERAPEUTICS AG : Regulation FD Disclosure, Financial Statements and Exh..
06/09 NABRIVA THERAPEUTICS AG : Other Events, Financial Statements and Exhibits (form ..
06/06 NABRIVA THERAPEUTICS : Announces Webcast of Analyst & Investor Day on June 19, 2..
06/05 Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, ..
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/15Nabriva Therapeutics AG downgraded by Zacks Investment Research to hold.  
08/14Wedbush Lowers Nabriva Therapeutics AG Q3 2017 Earnings Estimates to ($0.58) .. 
08/13Vivo Capital LLC Holds Position in Nabriva Therapeutics AG $NBRV  
08/10Cantor Fitzgerald Comments on Nabriva Therapeutics AG’s FY2017 Earnings $NBRV.. 
08/10Nabriva Therapeutics AG upgraded by Zacks Investment Research to buy. $12.00 .. 
More tweets
Qtime:8
News from SeekingAlpha
08/07 Nabriva Therapeutics beats by $0.06, misses on revenue
07/11 Nabriva Therapeutics appoints Francesco Maria Lavino as CCO
06/23 FDA To Discuss Mylotarg Again And Nabriva's Pivotal Antibiotic Data
06/19 FDA OKs new antibiotic to fight ABSSSI
06/19 Nabriva Therapeutics (NBRV) Investor Presentation - Slideshow
Chart NABRIVA THERAPEUTICS PLC -
Duration : Period :
Nabriva Therapeutics PLC - Technical Analysis Chart | NBRV | US62957M1045 | 4-Traders
Technical analysis trends NABRIVA THERAPEUTICS PLC -
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 16,4 $
Spread / Average Target 86%
Managers
NameTitle
Colin Broom Chief Executive Officer & Director
Daniel D. Burgess Chairman
Gary L. Sender Chief Financial Officer
Elyse G. Seltzer Chief Medical Officer
Thomas Lembck Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
NABRIVA THERAPEUTICS PLC - ADR48.15%237
AMGEN14.77%122 447
CELGENE CORPORATION10.22%99 812
GILEAD SCIENCES1.02%94 471
REGENERON PHARMACEUTICALS27.64%49 721
VERTEX PHARMACEUTICALS101.63%37 450